226 related articles for article (PubMed ID: 22957729)
1. CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation.
Sala M; Braida D; Pucci L; Manfredi I; Marks MJ; Wageman CR; Grady SR; Loi B; Fucile S; Fasoli F; Zoli M; Tasso B; Sparatore F; Clementi F; Gotti C
Br J Pharmacol; 2013 Feb; 168(4):835-49. PubMed ID: 22957729
[TBL] [Abstract][Full Text] [Related]
2. Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.
Peng C; Stokes C; Mineur YS; Picciotto MR; Tian C; Eibl C; Tomassoli I; Guendisch D; Papke RL
J Pharmacol Exp Ther; 2013 Nov; 347(2):424-37. PubMed ID: 23959137
[TBL] [Abstract][Full Text] [Related]
3. Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells.
Riganti L; Matteoni C; Di Angelantonio S; Nistri A; Gaimarri A; Sparatore F; Canu-Boido C; Clementi F; Gotti C
Br J Pharmacol; 2005 Dec; 146(8):1096-109. PubMed ID: 16273122
[TBL] [Abstract][Full Text] [Related]
4. Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.
Braida D; Ponzoni L; Martucci R; Sparatore F; Gotti C; Sala M
Psychopharmacology (Berl); 2014 May; 231(9):1975-85. PubMed ID: 24311357
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
6. The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.
Ponzoni L; Braida D; Pucci L; Andrea D; Fasoli F; Manfredi I; Papke RL; Stokes C; Cannazza G; Clementi F; Gotti C; Sala M
Psychopharmacology (Berl); 2014 Dec; 231(24):4681-93. PubMed ID: 24862365
[TBL] [Abstract][Full Text] [Related]
7. Agonist and antagonist effects of cytisine in vivo.
Radchenko EV; Dravolina OA; Bespalov AY
Neuropharmacology; 2015 Aug; 95():206-14. PubMed ID: 25839895
[TBL] [Abstract][Full Text] [Related]
8. The contribution of α4β2 and non-α4β2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice.
de Moura FB; McMahon LR
Psychopharmacology (Berl); 2017 Mar; 234(5):781-792. PubMed ID: 28028600
[TBL] [Abstract][Full Text] [Related]
9. The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Cunningham CS; McMahon LR
Eur J Pharmacol; 2011 Mar; 654(1):47-52. PubMed ID: 21172344
[TBL] [Abstract][Full Text] [Related]
10. Cytisine-based nicotinic partial agonists as novel antidepressant compounds.
Mineur YS; Eibl C; Young G; Kochevar C; Papke RL; Gündisch D; Picciotto MR
J Pharmacol Exp Ther; 2009 Apr; 329(1):377-86. PubMed ID: 19164465
[TBL] [Abstract][Full Text] [Related]
11. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
12. In pursuit of alpha4beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine.
Coe JW; Vetelino MG; Bashore CG; Wirtz MC; Brooks PR; Arnold EP; Lebel LA; Fox CB; Sands SB; Davis TI; Schulz DW; Rollema H; Tingley FD; O'Neill BT
Bioorg Med Chem Lett; 2005 Jun; 15(12):2974-9. PubMed ID: 15908213
[TBL] [Abstract][Full Text] [Related]
13. α6β2*-subtype nicotinic acetylcholine receptors are more sensitive than α4β2*-subtype receptors to regulation by chronic nicotine administration.
Marks MJ; Grady SR; Salminen O; Paley MA; Wageman CR; McIntosh JM; Whiteaker P
J Neurochem; 2014 Jul; 130(2):185-98. PubMed ID: 24661093
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
15. C3-halogenation of cytisine generates potent and efficacious nicotinic receptor agonists.
Abin-Carriquiry JA; Voutilainen MH; Barik J; Cassels BK; Iturriaga-Vásquez P; Bermudez I; Durand C; Dajas F; Wonnacott S
Eur J Pharmacol; 2006 Apr; 536(1-2):1-11. PubMed ID: 16563372
[TBL] [Abstract][Full Text] [Related]
16. Structural characterization of binding mode of smoking cessation drugs to nicotinic acetylcholine receptors through study of ligand complexes with acetylcholine-binding protein.
Rucktooa P; Haseler CA; van Elk R; Smit AB; Gallagher T; Sixma TK
J Biol Chem; 2012 Jul; 287(28):23283-93. PubMed ID: 22553201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo neuronal nicotinic receptor properties of (+)- and (-)-pyrido[3,4]homotropane [(+)- and (-)-PHT]: (+)-PHT is a potent and selective full agonist at α6β2 containing neuronal nicotinic acetylcholine receptors.
Carroll FI; Navarro HA; Mascarella SW; Castro AH; Luetje CW; Wageman CR; Marks MJ; Jackson A; Damaj MI
ACS Chem Neurosci; 2015 Jun; 6(6):920-6. PubMed ID: 25891987
[TBL] [Abstract][Full Text] [Related]
19. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
[TBL] [Abstract][Full Text] [Related]
20. Nicotinic receptor partial agonists alter catecholamine homeostasis and response to nicotine in PC12 cells.
Turcanu DS; Kirtok N; Eibl C; Guendisch D; LaGamma EF; Nankova BB
Neurosci Lett; 2012 May; 516(2):212-6. PubMed ID: 22503726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
